A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)Xudong Zhang, Mingzhi Zhang, Shanshan Ma et al.|Blood|2022Cited by 4